204 related articles for article (PubMed ID: 8330765)
1. Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia.
Koh SC; Anandakumar C; Montan S; Ratnam SS
Gynecol Obstet Invest; 1993; 35(4):214-21. PubMed ID: 8330765
[TBL] [Abstract][Full Text] [Related]
2. Coagulation and fibrinolysis in preeclampsia and neonates.
Tanjung MT; Siddik HD; Hariman H; Koh SC
Clin Appl Thromb Hemost; 2005 Oct; 11(4):467-73. PubMed ID: 16244774
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Nakashima A; Kobayashi T; Terao T
Gynecol Obstet Invest; 1996; 42(2):95-101. PubMed ID: 8878712
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activators and their inhibitors in leukemic cell homogenates.
Wada H; Kumeda Y; Ogasawara Z; Ohiwa M; Kaneko T; Tamaki S; Ohno T; Kageyama S; Kobayashi T; Deguchi K
Am J Hematol; 1993 Feb; 42(2):166-70. PubMed ID: 8438877
[TBL] [Abstract][Full Text] [Related]
6. Blood coagulation and fibrinolysis during normal pregnancy.
van Wersch JW; Ubachs JM
Eur J Clin Chem Clin Biochem; 1991 Jan; 29(1):45-50. PubMed ID: 1904779
[TBL] [Abstract][Full Text] [Related]
7. Contribution of platelets to increased plasminogen activator inhibitor type 1 in severe preeclampsia.
Gilabert J; Estellés A; Aznar J; España F; Andrés C; Santos T; Vallés J
Thromb Haemost; 1990 Jun; 63(3):361-6. PubMed ID: 2144918
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Tran-Thang C; Fasel-Felley J; Pralong G; Hofstetter JR; Bachmann F; Kruithof EK
Thromb Haemost; 1989 Sep; 62(2):651-3. PubMed ID: 2510345
[TBL] [Abstract][Full Text] [Related]
10. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
[TBL] [Abstract][Full Text] [Related]
11. Enhanced PAI-1 levels from early second trimester and during labour and plasminogen activators in normal pregnancy.
Koh SC; Anandakumar C; Biswas A; Fong YF
Thromb Haemost; 2002 Jan; 87(1):175-6. PubMed ID: 11858184
[No Abstract] [Full Text] [Related]
12. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
13. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
Prasad RN; Koh SC; Viegas OA; Ratnam SS
Clin Appl Thromb Hemost; 1999 Jan; 5(1):60-70. PubMed ID: 10725985
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors.
Kruithof EK; Tran-Thang C; Gudinchet A; Hauert J; Nicoloso G; Genton C; Welti H; Bachmann F
Blood; 1987 Feb; 69(2):460-6. PubMed ID: 2432970
[TBL] [Abstract][Full Text] [Related]
15. Haemostatic factors in women with history of preeclampsia.
Portelinha A; Cerdeira AS; Belo L; Braga J; Tejera E; Pinto A; Pinto F; Areias MJ; Patrício B; Rebelo I
Thromb Res; 2009 May; 124(1):52-6. PubMed ID: 19049844
[TBL] [Abstract][Full Text] [Related]
16. Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia.
Mutoh S; Kobayashi M; Hirata J; Itoh N; Maki M; Komatsu Y; Yoshida A; Sasa H; Kuroda K; Kikuchi Y
Agents Actions Suppl; 1992; 38 ( Pt 2)():342-9. PubMed ID: 1462840
[TBL] [Abstract][Full Text] [Related]
17. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia.
Halligan A; Bonnar J; Sheppard B; Darling M; Walshe J
Br J Obstet Gynaecol; 1994 Jun; 101(6):488-92. PubMed ID: 8018635
[TBL] [Abstract][Full Text] [Related]
18. Clinical and haemostatic parameters in the HELLP syndrome: relevance of plasminogen activator inhibitors.
Gilabert J; Estellés A; Ridocci F; España F; Aznar J; Galbis M
Gynecol Obstet Invest; 1990; 30(2):81-6. PubMed ID: 2147163
[TBL] [Abstract][Full Text] [Related]
19. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
20. Influence of delivery on plasminogen activator inhibitor activity.
Koelbl H; Kirchheimer J; Tatra G
J Perinat Med; 1989; 17(2):107-11. PubMed ID: 2681664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
